Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark of many cancers.
MATERIALS AND METHODS

Breast cancer samples
For lipidomic profiling breast cancer tissue as well as adjacent normal tissue was dissected by a senior pathologist in the operating room and was immediately frozen in liquid nitrogen and stored at -80°C. The histopathological quality control of the samples is explained in the Supplementary Materials and Methods.
As control samples paired normal breast tissue was used. It was obtained at the time of tumor surgery but did not contain tumor cells. From formalin-fixed paraffin-embedded (FFPE) tissue of the same tumors a tissue microarray (TMA) was constructed for immunohistochemical evaluation of protein markers. The investigations were performed in the framework of the METAcancer FP7 project -ethic committee approval was obtained from the institutional review board of the Charité hospital.
Lipidomic analyses of breast cancer tissue
The full details of the lipidomics methods are explained in the Supplementary Materials and Methods. In brief, the lipid extracts were analysed on a Waters Q-Tof Premier mass spectrometer combined with an Acquity Ultra Performance LC TM (UPLC   TM   ) . The data were processed using MZmine 2 software (13) and the lipid identification was based on an internal spectral library and tandem mass spectrometry. The lipidomics results were normalized according to the protein content of the samples (mg protein / mg tissue) and the lipids were quantified using the internal standards.
In silico data mining and gene selection for functional studies
A list of 24 genes involved in lipid metabolism was collected and GeneSapiens database (14) was applied to bioinformatically explore the gene expression levels across 9783 human tissue samples.
Research. 
Immunohistochemistry
The antibodies and detailed procedures of immunohistochemical staining on tissue microarrays are found in the Supplementary Materials and Methods. The stainings were evaluated by two pathologists (S.B. and B.M.). The intensity (negative, weak, moderate, strong) and the percentage of positive tumor cells were evaluated, and from these parameters an immunoreactive score (IRS) was calculated as described before (15) . The following cutoffs were used in the analysis of the different markers: FASN and INSIG1, low = IRS 0-4 vs. high = IRS 6-12; ACACA and SREBP1, low = IRS 0-2 vs. high = IRS 3-12.
Functional experiments in breast cancer cells
The details and materials of the cell line experiments can be found in the Supplementary Materials and Methods. The experiments were performed in breast carcinoma cells ZR-75-1 and MDA-MB-468 and in non-malignant MCF-10A cell line. After 72 h incubation, cells were assayed for viability and apoptosis.
Scrambled siRNA and lipid only were used as negative controls, siRNAs against KIF11 (kinesin family member 11) and PLK1 (polo-like kinase 1) as positive controls. Based on the cell viability results seven siRNAs (and two positive controls) were selected for lipidomics analysis. To validate the silencing of the target genes, real-time quantitative PCR was performed from each sample prepared for lipidome analysis.
Statistical analyses of the data
All statistical analyses and visualizations were performed using R software, version 2.9.1, and the details of all the analyses can be found in the Supplementary Materials and Methods. The differences between the tumor types were compared using the Wilcoxon rank-sum test. To account for the multiple testing issues, q-values indicating the false discovery rate were calculated with the R package qvalue. Median values were used for calculating fold changes and constructing heatmaps. Predictive model for ER status (Fig. 1C) 
RESULTS
Lipidomic analysis of breast cancer tissue
Global lipidomic analysis using Ultra Performance Liquid Chromatography -Mass Spectrometry (UPLC TM -MS) methodology was performed on 257 breast cancer samples as well as 10 samples from adjacent breast tissue. Before the start of the data-acquisition, the samples were separated into two groups (Supplementary Table S2 ) using the Kullback-Leibler divergence to ensure a comparable distribution of clinicopathological variables. The initial results were derived from the training cohort of 183 samples, and the second cohort consisting of 84 samples was used to validate the results. Both positive (ESI+) and negative (ESI-) electrospray ionization modes were used in MS analyses. ESI+ is more sensitive than ESI-and shows neutral lipids, such as triacylglycerols (TGs), but ESI-was relevant in this study due to sensitivity to detect the negatively charged signaling and membrane lipids including phosphatidylinositols (PIs) and phosphatidylethanolamines (PEs). A total of 425 lipids were detected in ESI+ mode and 126 lipids in ESImode. Supplementary Table S3 shows mass-to-charge (m/z) values, retention times and abundance of the lipids in the training and validation cohorts. The overlapping lipids in these ion modes showed very similar results, and, unless otherwise stated, we report here only the ESI-data (ESI+ data shown in Supplementary   Table S4 ). The lipids were identified by tandem mass spectrometry, and those for which the exact structure of the two acyl chains could not be elucidated, the total number of carbon atoms and double bonds (e.g. PC(32:1)) is shown.
Tumor grade and ER status associate with altered membrane lipid composition
The most striking difference in the lipid profiles were observed between the breast tumor and normal tissue samples. The False Discovery rate (FDR) q-values were significant for 70% of the lipids even with a very stringent cut-off value (q<0.001). The membrane phospholipids including phosphatidylcholines (PCs), Table S4 ).
In tumors, the most prominent difference associated with the altered phospholipid metabolism was related to estrogen receptor (ER) status (Table 1 and Supplementary Table S5 ). Many phospholipids (PCs, PEs, PIs) and SMs were upregulated in ER-tumors, whereas TGs were not different when comparing ER+ and ERbreast cancer samples (Supplementary Table S4 ). Some glycosylated ceramides were highly downregulated in ER-tumors (Table 1 and Supplementary Table S5 ).
Another important parameter associating with the tissue phospholipid profiles was tumor grade. Since no large differences were observed between grade 1 and 2 tumors (data not shown), we first combined these into one group, and compared this group to grade 3 tumors. Interestingly, the most significantly changed lipids were the same that were also affected by the ER status. In fact, 17 out of the 22 most altered lipids were found in both ranked lists (grade and ER status; Table 1 , complete data shown in Supplementary   Tables S5 (ESI-) It is known that the majority of the ER-tumors are of grade 3 (17) , and this was also the case in our patient population since only 7% of the grade 1&2 tumors were ER-, while 44% of the grade 3 tumors were ER-.
Thus, either grade or ER status alone could explain our results. We therefore analyzed the ER status only within grade 3 tumors and the grade only within ER+ tumors, and confirmed that both ER status and grade independently affected the same lipids (Fig. 1B and Supplementary Table S7) , with the highest levels found in ER-grade 3 tumors (the only exception being the glycosylated ceramide, which was only slightly affected by tumor grade but highly downregulated in ER-tumors).
Interestingly, the most significantly increased lipids (Table 1) (18, 19) . Indeed, a common characteristic for the altered lipids was the incorporation of at least one saturated fatty acyl side chain, either palmitate or stearic acid, the latter one being also the first product of the elongases. The results indicate that the de novo synthesized fatty acids incorporated into the membrane phospholipids are increased in tumors as compared with healthy tissue, and this process further increases during cancer progression, i.e. in ER-and grade 3 tumors. Of the unsaturated fatty acids, arachidonic acid (C20:4) was the most commonly identified in the phospholipids.
We also tested if the results could be validated in the validation cohort. This series did not contain normal tissue samples, and therefore normal breast to tumor comparison could not be performed. The results for the ER status were highly reproducible in this independent sample series ( Table 1) . For grade, q-values were not as strong as the ones obtained for ER status, but the results showed similar trends with the training set. We also applied predictive regression models for tumor grade and ER status using the training Progesterone receptor (PR) and HER2 status did not cause as dramatic alterations in the lipid profiles as the ER status and grade. However, similar to ER status, also PR negativity was associated with downregulation of glycosylated ceramides, and some phospholipids (e.g. PC(32:1) and PC(32:2)) were increased in HER2+ tumors both in the training (Supplementary Tables S4 and S5 ) and validation sets (data not shown).
Tumor membrane lipid composition is associated with patient survival
Since many lipids were associated with tumor parameters predicting worse prognosis, such as grade 3 and ER-status (17), we also studied associations of lipidomic profiles with the survival of the patients. For these analyses, both ESI-and ESI+ data were used, and the patients were divided into two populations for each lipid, grouped according to concentration above or below the median value across all samples. Several Fig. 1D ). All of these lipids were increased in grade 3 tumors, which may explain their association to poorer survival.
Expression of selected lipid metabolism related proteins associates with altered lipid profiles
In order to link the observed lipidomic changes to expression of lipid-related genes, we carried out a comprehensive bioinformatic analysis of the mRNA expression profiles for multiple genes across datasets of 9783 tissue samples representing 43 healthy and 68 malignant tissue types in the GeneSapiens database (14) . Based on the expression and function of the genes, we selected several genes (Fig. 2) for follow-up studies by immunohistochemistry in clinical tumors and functional gene silencing studies in breast cancer cells. The selected genes function in many aspects of lipid metabolism, as illustrated in Fig. 2 . The expression of these genes in the database is shown in Supplementary Fig. S1 . In summary, ACACA, SCD, SREBP1 and THRSP were highly expressed in clinical breast cancer samples.
In order to integrate lipidomics results with gene expression, immunohistochemical stainings were performed in the same samples for which lipidomic profiles were determined. Following the initial screening to determine which of the above selected gene products were significantly altered in tumors, we finally studied four proteins: ACACA, FASN, INSIG1 and SREBP1 (Fig. 3A) . Based on the staining intensity and percentage of positive tumor cells the samples were divided for each protein into two categories (low and high). While ER and HER2 status did not associate with changes in protein expression, differences were found for the tumor grade (Supplementary Table S8 ), in particular for ACACA, as the group containing low levels of this protein had 24% of grade 3 tumors, while the high level group had 51% of grade 3 tumors. Also INSIG1 and SREBP1 showed differences (high expression found in low grade tumors), although the results were not statistically significant. Interestingly, although lipidomics showed similar results in ER-and grade 3 tumors, this phenomenon was not evident in the immunohistochemistry results for these four proteins.
To correlate the gene expression with lipidomics results, we investigated the levels of the phospholipids from Table 1 in the groups with either low or high expression of the proteins. Unsupervised hierarchical clustering revealed two major clusters (Fig. 3B) . High expression of FASN and ACACA together with low expression of SREBP1 formed a cluster in which the levels of the phospholipids were considerably higher as 
compared to the other cluster. This finding is in accordance to the expectations, since FASN and ACACA are known to increase fatty acid de novo synthesis. In addition, the association of the low SREBP1 expressing group with high phospholipid levels was anticipated based on the results showing that this group had more grade 3 tumors than the high expressing group.
Gene silencing reveals that de novo fatty acid synthesis and phospholipid remodeling pathways are required for breast cancer cell growth
In order to establish a direct role of selected genes in regulating the observed phospholipid remodeling, we performed gene silencing studies of seven genes ( (Fig. 4A) . The results indicated that ELOVL1, FASN, SCD and SCAP siRNAs silenced their target genes efficiently (>50% of the scrambled control) whereas for ACACA, THRSP and INSIG1 silencing was only partial. All the genes were shown to reduce cell viability significantly (Fig. 4B) , and the phenomenon was observed with multiple siRNAs per gene. SCD silencing had the strongest effects, resulting in the reduction of cell growth to 30% of the levels seen with scrambled control siRNAs. ACACA (44%), INSIG1 (50%) and ELOVL1 (52%) silencing also had a strong impact on cell survival, and THRSP1 and FASN siRNA transfections reduced cell viability to 60% and 63% and SCAP siRNA to 76% of the scrambled control. Importantly, ACACA showed a strong effect, as already a partial silencing led to significant decrease in cell viability. An increase (20% relative to the control) in apoptosis was seen by FASN knock-down (Fig. 4C) . Silencing of four of the Table S9 ).
To study whether the observed changes in cell viability were specific for malignant cells, silencing experiments were also performed in non-malignant MCF-10A breast epithelial cells. The results showed that these genes are also important for viability in these cells (Fig. 4E and 4F) . However, the transfection efficacy of MCF-10A cells was extremely good, and if the cell viability results are compared to the transfection efficacies in the respective cell lines, the silencing of all these genes, apart from SCAP, had a stronger impact in cancer cells compared to the non-malignant ones ( Fig. 4E and 4F) . A stronger effect was observed in ZR-75-1 cells than in the MDA-MB-468 cells, which is understandable based on the high expression of lipogenic genes in ZR-75-1 cells (Supplementary Fig. S2 ). Notably, apart from INSIG1, the gene expression was not statistically different between the MDA-MB-468 and MCF-10A cells, yet the relative effect of silencing was stronger in cancer cells.
In order to compare the molecular lipid changes in in vitro functional assays with those of tumor tissues, the lipid profiles were measured from the siRNA-treated ZR-75-1 breast cancer cells at 48h and 72h after transfection, and compared to the respective control samples. Fig. 4D shows the levels of those phospholipids that were found to be most strongly associated with grade and ER status (Table 1) In the study we identified metabolic enzymes that have not been studied intensively in cancer before.
ELOVL1 is an enzyme elongating saturated and monounsaturated fatty acids (22) , which were detected at high levels in the phospholipids of cancer samples. Although ELOVL1 mRNA was not overexpressed in breast cancer compared to normal breast, the gene silencing results indicated that ELOVL1 is vital for breast cancer cells. SCD is a desaturase converting palmitic (C16:0) and stearic (C18:0) acids to palmitoleic (C16:1) and oleic (C18:1) acids, respectively. It has been reported to be downregulated in prostate cancer, but shown to have an important role in the tumorigenesis of hepatocellular carcinomas and lung Although attempts to investigate lipids during carcinogenesis were reported decades ago (34) , the present study is the first one to characterize the molecular lipid changes in breast cancer. The lipid metabolism is an attractive target for cancer therapy, as it differs between tumors and normal tissues, with the most dramatic changes observed in the most aggressive tumors. Our results show that only comprehensive understanding, both at the gene expression and metabolite levels, will provide the information on the most crucial components of the lipid metabolism in tumor cells that could be exploited as therapeutic targets. phospholipids from Table 1 in tumors with either low or high expression of the selected lipid metabolism proteins. The low and high expression were defined based on the immunoreactive score, which takes into account both the intensity and area of the staining, and the median of samples within each group was compared to the median of all samples by log2 fold change. 
TABLES
